NYU Langone Medical Center will lead a 5-year, 60-center clinical trial to evaluate new treatment protocols for herpes zoster ophthalmicus (HZO), a form of shingles that can seriously and permanently affect the eye. The project is being funded through a $15 million grant from the National Eye Institute, a division of the National Institutes of Health.
Entitled the Zoster Eye Disease Study (ZEDS), it will investigate the longer-term use of suppressive antiviral medication to reduce complications of HZO, which can lead to loss of vision, itching above the eye, chronic pain, and even stroke.
Elisabeth J. Cohen, MD, professor of ophthalmology at NYU Langone who will serve as principal investigator on the study, has focused her research primarily on this disease after suffering from it herself in 2008, resulting in a permanent impairment of her vision. In addition to creating and advocating for ZEDS, she has worked on national efforts to promote the vaccine to prevent shingles.
“There is no greater champion for this initiative than Dr. Elisabeth Cohen,” says Joel S. Schuman, MD, professor in the departments of Ophthalmology and Neuroscience and Physiology and chair of the Department of Ophthalmology at NYU Langone. “She and the other clinical researchers and clinicians on this study have enormous opportunity to improve the health of millions of people worldwide suffering from herpes zoster.”
Read more at NYU Langone Medical Center
